vs
Side-by-side financial comparison of ADDENTAX GROUP CORP. (ATXG) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.
ADDENTAX GROUP CORP. is the larger business by last-quarter revenue ($975.8K vs $820.2K, roughly 1.2× InMed Pharmaceuticals Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -430.0%, a 182.7% gap on every dollar of revenue. On growth, ADDENTAX GROUP CORP. posted the faster year-over-year revenue change (-7.9% vs -26.2%). Over the past eight quarters, ADDENTAX GROUP CORP.'s revenue compounded faster (-13.3% CAGR vs -16.4%).
Addentax Group Corp designs, manufactures and distributes functional workwear, protective clothing and customized uniforms. It also provides integrated apparel supply chain solutions for corporate, industrial and apparel brand clients across North America, Europe and the Asia-Pacific region.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
ATXG vs INM — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $975.8K | $820.2K |
| Net Profit | $-4.2M | $-2.0M |
| Gross Margin | 30.2% | 22.5% |
| Operating Margin | -7.0% | -247.3% |
| Net Margin | -430.0% | -247.3% |
| Revenue YoY | -7.9% | -26.2% |
| Net Profit YoY | -286.5% | 21.2% |
| EPS (diluted) | — | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $975.8K | $820.2K | ||
| Q3 25 | $820.7K | $1.1M | ||
| Q2 25 | $981.0K | $1.3M | ||
| Q1 25 | $1.4M | $1.3M | ||
| Q4 24 | $864.9K | $1.1M | ||
| Q3 24 | $1.1M | $1.3M | ||
| Q2 24 | $851.0K | $1.3M | ||
| Q1 24 | $1.3M | $1.2M |
| Q4 25 | $-4.2M | $-2.0M | ||
| Q3 25 | $-102.8K | $-1.7M | ||
| Q2 25 | $-392.4K | $-1.8M | ||
| Q1 25 | $-2.1M | $-2.1M | ||
| Q4 24 | $-1.1M | $-2.6M | ||
| Q3 24 | $-721.5K | $-1.7M | ||
| Q2 24 | $-1.2M | $-1.9M | ||
| Q1 24 | $864.6K | $-1.7M |
| Q4 25 | 30.2% | 22.5% | ||
| Q3 25 | 27.4% | 36.0% | ||
| Q2 25 | 0.6% | 44.2% | ||
| Q1 25 | -17.0% | 13.9% | ||
| Q4 24 | 22.0% | 41.5% | ||
| Q3 24 | 42.3% | 39.0% | ||
| Q2 24 | 23.8% | 36.3% | ||
| Q1 24 | 24.1% | 24.7% |
| Q4 25 | -7.0% | -247.3% | ||
| Q3 25 | -54.8% | -154.2% | ||
| Q2 25 | -63.9% | -137.1% | ||
| Q1 25 | -82.9% | -168.1% | ||
| Q4 24 | -17.3% | -231.6% | ||
| Q3 24 | -3.7% | -132.7% | ||
| Q2 24 | -59.3% | -150.5% | ||
| Q1 24 | -8.9% | -146.9% |
| Q4 25 | -430.0% | -247.3% | ||
| Q3 25 | -12.5% | -154.2% | ||
| Q2 25 | -40.0% | -137.1% | ||
| Q1 25 | -152.8% | -168.1% | ||
| Q4 24 | -125.5% | -231.6% | ||
| Q3 24 | -64.8% | -132.7% | ||
| Q2 24 | -143.5% | -151.0% | ||
| Q1 24 | 66.6% | -146.9% |
| Q4 25 | — | $-0.51 | ||
| Q3 25 | — | $-0.44 | ||
| Q2 25 | $-0.06 | $-0.07 | ||
| Q1 25 | $-0.28 | $-1.94 | ||
| Q4 24 | $-0.19 | $-3.64 | ||
| Q3 24 | $-0.13 | $-2.71 | ||
| Q2 24 | $-0.25 | $2.39 | ||
| Q1 24 | $0.41 | $-3.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.5K | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $21.6M | $9.6M |
| Total Assets | $28.2M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.5K | $7.0M | ||
| Q3 25 | $445.7K | $9.4M | ||
| Q2 25 | $490.7K | $11.1M | ||
| Q1 25 | $325.0K | $4.7M | ||
| Q4 24 | $480.1K | $3.5M | ||
| Q3 24 | $810.5K | $5.6M | ||
| Q2 24 | $904.2K | $6.6M | ||
| Q1 24 | $816.2K | — |
| Q4 25 | $21.6M | $9.6M | ||
| Q3 25 | $25.9M | $11.6M | ||
| Q2 25 | $25.2M | $13.4M | ||
| Q1 25 | $21.7M | $7.0M | ||
| Q4 24 | $23.8M | $6.2M | ||
| Q3 24 | $24.8M | $8.4M | ||
| Q2 24 | $25.5M | $9.2M | ||
| Q1 24 | $26.0M | $11.1M |
| Q4 25 | $28.2M | $11.2M | ||
| Q3 25 | $28.2M | $13.4M | ||
| Q2 25 | $49.0M | $15.6M | ||
| Q1 25 | $49.2M | $9.3M | ||
| Q4 24 | $49.6M | $8.5M | ||
| Q3 24 | $50.6M | $10.5M | ||
| Q2 24 | $52.0M | $11.8M | ||
| Q1 24 | $52.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-114.9K | $-2.4M |
| Free Cash FlowOCF − Capex | $-147.7K | — |
| FCF MarginFCF / Revenue | -15.1% | — |
| Capex IntensityCapex / Revenue | 3.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-114.9K | $-2.4M | ||
| Q3 25 | $-661.4K | $-1.6M | ||
| Q2 25 | $-306.1K | $-1.8M | ||
| Q1 25 | $13.6K | $-1.7M | ||
| Q4 24 | $273.4K | $-2.5M | ||
| Q3 24 | $722.2K | $-1.8M | ||
| Q2 24 | $-193.2K | $-1.0M | ||
| Q1 24 | $1.1M | $-1.9M |
| Q4 25 | $-147.7K | — | ||
| Q3 25 | $-700.0K | — | ||
| Q2 25 | $-383.9K | — | ||
| Q1 25 | $-38.5K | — | ||
| Q4 24 | $235.3K | — | ||
| Q3 24 | $642.1K | — | ||
| Q2 24 | $-220.5K | — | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | -15.1% | — | ||
| Q3 25 | -85.3% | — | ||
| Q2 25 | -39.1% | — | ||
| Q1 25 | -2.8% | — | ||
| Q4 24 | 27.2% | — | ||
| Q3 24 | 57.7% | — | ||
| Q2 24 | -25.9% | — | ||
| Q1 24 | — | -165.0% |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 7.9% | — | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
